unoprostone isopropyl   Click here for help

GtoPdb Ligand ID: 8282

Synonyms: Rescula® (proposed trade name) | UF 021 | UF-021
Approved drug
unoprostone isopropyl is an approved drug (FDA (2000))
Compound class: Synthetic organic
Comment: Note that the INN for this compound is for the carboxylic acid, whereas the compound used clinically is the isopropyl ester.
Unoprostone was originally developed as an intraocular pressure-reducing agent for use in glaucoma, however use for this indication has been discontinued. The focus is now on unoprostone's ability to treat retinal disease [3,5].
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: unoprostone isopropyl

unoprostone isopropyl is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 17
Topological polar surface area 83.83
Molecular weight 424.32
XLogP 5.39
No. Lipinski's rules broken 2

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CCCCCCCC(=O)CCC1C(O)CC(C1CC=CCCCC(=O)OC(C)C)O
Isomeric SMILES CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@@H]([C@@H]1C/C=C\CCCC(=O)OC(C)C)O
InChI InChI=1S/C25H44O5/c1-4-5-6-7-10-13-20(26)16-17-22-21(23(27)18-24(22)28)14-11-8-9-12-15-25(29)30-19(2)3/h8,11,19,21-24,27-28H,4-7,9-10,12-18H2,1-3H3/b11-8-/t21-,22-,23+,24-/m1/s1
InChI Key XXUPXHKCPIKWLR-JHUOEJJVSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
References
1. Bazan NG. (2006)
The onset of brain injury and neurodegeneration triggers the synthesis of docosanoid neuroprotective signaling.
Cell Mol Neurobiol, 26 (4-6): 901-13. [PMID:16897369]
2. Cuppoletti J, Malinowska DH, Tewari KP, Chakrabarti J, Ueno R. (2007)
Cellular and molecular effects of unoprostone as a BK channel activator.
Biochim Biophys Acta, 1768 (5): 1083-92. [PMID:17307133]
3. Harms NV, Toris CB. (2013)
Current status of unoprostone for the management of glaucoma and the future of its use in the treatment of retinal disease.
Expert Opin Pharmacother, 14 (1): 105-13. [PMID:23199345]
4. Sharif NA, Kelly CR, Crider JY. (2003)
Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues.
Invest Ophthalmol Vis Sci, 44 (2): 715-21. [PMID:12556403]
5. Tawada A, Sugawara T, Ogata K, Hagiwara A, Yamamoto S. (2013)
Improvement of central retinal sensitivity six months after topical isopropyl unoprostone in patients with retinitis pigmentosa.
Indian J Ophthalmol, 61 (3): 95-9. [PMID:23514642]
6. Tsuruma K, Tanaka Y, Shimazawa M, Mashima Y, Hara H. (2011)
Unoprostone reduces oxidative stress- and light-induced retinal cell death, and phagocytotic dysfunction, by activating BK channels.
Mol Vis, 17: 3556-65. [PMID:22219651]
7. Yamamoto S, Sugawara T, Murakami A, Nakazawa M, Nao-I N, Machida S, Wada Y, Mashima Y, Myake Y. (2012)
Topical isopropyl unoprostone for retinitis pigmentosa: microperimetric results of the phase 2 clinical study.
Ophthalmol Ther, 1 (1): 5. [PMID:25135585]